Answers are grounded in this paper and cite their sources.
The undersigned submits this petition to request the Commissioner of Food and Drugs to immediately require the addition of boxed warnings, warnings, precautions, and highlights of prescribing information to the product label for all selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) products, including branded and generic formulations.
No takes yet. Share an insight, caveat, or question.
David Healy (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: